01—Abstract
Summary
Summary of the 10-Q filed August 6, 2024. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. reported a strong second quarter of 2024, with total revenues of $637.2 milliona for the three months ended June 30, 2024, up from $469.8 million a year earlier, and net income of $226.1 million, or $0.77 per diluted share, compared with $81.2 million, or $0.25 per diluted share, in the prior-year quarter.
The result was driven largely by license revenues of $195.0 millionb, which include a $150.0 million commercial milestone from Ipsen tied to $600.0 million in cumulative cabozantinib net sales over four consecutive quarters. Net product revenues rose to $437.6 million from $409.6 million, with CABOMETYX sales increasing on higher unit volume following the approval of CABOMETYX in combination with nivolumab for first-line advanced RCC. For the six months ended June 30, 2024, total revenues were $1.06 billion and net income was $263.4 million.
Results for the period also reflect $33.3 millionc in restructuring expenses under the 2024 Restructuring Plan, which was substantially completed by the end of the second quarter. Cash, cash equivalents and investments totaled $1.4 billion at June 30, 2024, down from $1.7 billion at December 31, 2023, reflecting $450.0 million of share repurchases completed under the program authorized in January 2024. In August 2024, the Board authorized a new repurchase program of up to $500.0 million through the end of 2025.
The filing also highlights ongoing legal and pipeline developments. Settlements with Cipla and earlier with Teva provide U.S. generic entry for CABOMETYX no earlier than January 1, 2031, while the MSN II litigation remains pending with a judgment expected in the second half of 2024. On the pipeline side, the company reported an FDA-accepted sNDA for cabozantinib in pNET and epNET with a PDUFA date of April 3, 2025, and is discontinuing XB002 and prioritizing zanzalintinib, XL309 and XB010.
02—Key points
Key Highlights
- Total revenues of $637.2 million in Q2 2024, up from $469.8 million in Q2 2023, including $195.0 million in license revenues.
- Net income of $226.1 million ($0.77 per diluted share) in Q2 2024, versus $81.2 million ($0.25 per diluted share) in Q2 2023.
- A $150.0 million commercial milestone from Ipsen, recognized as license revenue in Q2 2024, was triggered by $600.0 million in cumulative cabozantinib net sales over four consecutive quarters.
- Net product revenues of $437.6 million, up from $409.6 million, driven by CABOMETYX unit volume growth following first-line RCC approval in combination with nivolumab.
- Restructuring expenses of $33.3 million for the six months ended June 30, 2024, under a 2024 Restructuring Plan that was substantially completed by the end of Q2.
- Cash, cash equivalents and investments of $1.4 billion at June 30, 2024, versus $1.7 billion at December 31, 2023, after completing $450.0 million of share repurchases; a new $500.0 million repurchase program was authorized in August 2024.
- Generic entry for CABOMETYX under the Cipla and Teva settlements is permitted no earlier than January 1, 2031, while the MSN II litigation remains pending.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, Exelixis kept $0.35.
- Revenue$637.2M100.0%
- Cost of revenue−$17.7M2.8%
- Gross profit$619.5M97.2%
- Operating costs−$343.6M53.9%
- Operating income$275.9M43.3%
- Interest, other & tax−$49.8M7.8%
- Net income$226.1M35.5%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 6, 2024Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $637.18M$469.85M | +35.6% |
| Cost of Revenue | $17.67M$17.70M | −0.2% |
| Gross Profit | $619.51M$452.14M | +37.0% |
| R&D Expenses | $211.15M$232.57M | −9.2% |
| SG&A Expenses | $132.01M$141.72M | −6.8% |
| Operating Expenses | $361.30M$392.00M | −7.8% |
| Operating Income | $275.87M$77.85M | +254.4% |
| Net Income | $226.12M$81.18M | +178.5% |
| EPS (Basic) | $0.78$0.25 | +212.0% |
| EPS (Diluted) | $0.77$0.25 | +208.0% |
| Shares Outstanding (Basic) | 289.22M324.20M | −10.8% |
| Shares Outstanding (Diluted) | 293.97M327.31M | −10.2% |
05—Questions
Frequently Asked Questions
What drove the increase in Exelixis's revenue in the second quarter of 2024?
Total revenues rose to $637.2 million from $469.8 million, mainly because license revenues increased to $195.0 million from $52.7 million. That figure includes a $150.0 million commercial milestone from Ipsen. Net product revenues also grew to $437.6 million from $409.6 million, reflecting higher CABOMETYX unit sales.
How much cash does Exelixis have, and how is it being used?
Exelixis reported $1.4 billion in cash, cash equivalents and investments at June 30, 2024, compared with $1.7 billion at December 31, 2023. The decline reflects $449.7 million in cash payments for share repurchases during the six months, and the company completed its $450.0 million repurchase program. In August 2024 the Board authorized up to $500.0 million in additional repurchases through 2025.
What is the outlook for generic competition to CABOMETYX?
The filing states that Exelixis settled with Teva and Cipla, granting licenses to market generic CABOMETYX in the U.S. beginning January 1, 2031, if approved by the FDA. The MSN II litigation is ongoing, with a judgment expected in the second half of 2024. The filing notes that earlier generic entry could significantly decrease U.S. CABOMETYX revenues.
What pipeline and regulatory events are highlighted for investors?
The FDA accepted an sNDA for cabozantinib in previously treated pNET and epNET with a PDUFA target action date of April 3, 2025. Exelixis is discontinuing XB002 and prioritizing zanzalintinib, XL309 and XB010. It also announced that it will not pursue a regulatory path for COSMIC-313 after the final overall survival analysis did not show a benefit.
What did the 2024 Restructuring Plan involve?
The plan was intended to reduce the workforce and rebalance the cost structure. Restructuring expenses totaled $33.3 million for the six months ended June 30, 2024, against total expected plan costs of $33.5 million. The plan included severance, asset impairment, and contract termination costs, and terminated certain in-licensing collaborations, with the company exiting two Greater Philadelphia area leases.
06—Continue